Cerebrolysin: Mechanism, Evidence, and Dosing Protocols

Research disclaimer: Cerebrolysin is sold for research purposes only and is not intended for human consumption. The information below is drawn from published scientific literature.

Evidence Tier

Multiple human RCTs. Cochrane systematic reviews. Regulatory approval in Austria, Germany, Russia, China, and throughout Asia and Eastern Europe. The highest level of clinical evidence in this review series — with important caveats about trial quality and the nature of a biological extract.

Cerebrolysin is not a research-only compound in much of the world. It is an approved pharmaceutical used clinically for Alzheimer’s disease, stroke, and traumatic brain injury. The clinical evidence base, while imperfect, is real.

What Is Cerebrolysin?

Cerebrolysin is a parenteral solution of low-molecular-weight peptides derived from purified porcine (pig) brain cortex proteins. It is manufactured by EVER Neuro Pharma in Austria and has been in clinical use since the 1950s — making it one of the longest-used peptide preparations in medicine.

Unlike every other compound reviewed on this site, Cerebrolysin is not a defined sequence peptide. It is a biological extract containing:

• Approximately 85% free amino acids
• Approximately 15% peptide fraction (molecular weights <10,000 Da)
• The active peptide fraction includes analogs of BDNF, NGF, CNTF (ciliary neurotrophic factor), and GDNF (glial-derived neurotrophic factor)

The peptide mixture composition varies between batches — a fundamental pharmacological limitation. EVER Neuro Pharma maintains quality specifications, but lot-to-lot variability in biological extracts is an inherent challenge.

Cerebrolysin must be administered by injection (IV or IM). The peptide components are degraded in the GI tract. It cannot be taken orally.

Mechanism of Action

Neurotrophin Delivery (Primary)

The most direct interpretation of Cerebrolysin’s mechanism: it delivers peptide analogs of endogenous neurotrophic factors — BDNF, NGF, CNTF, GDNF — that cross the blood-brain barrier and activate neurotrophin receptors (TrkB for BDNF, TrkA for NGF, etc.). Unlike Semax, which induces endogenous neurotrophin synthesis, Cerebrolysin delivers the signal molecules externally.

The small molecular weights of the active peptides are essential to this mechanism — full-length BDNF (27,000 Da) does not cross the blood-brain barrier. The low-MW peptide analogs in Cerebrolysin do.

Neuroprotection Against Excitotoxicity

Cerebrolysin reduces glutamate-induced excitotoxicity in neuronal cultures. This mechanism is particularly relevant to acute neurological injuries (stroke, TBI) where glutamate release into the extracellular space causes extensive secondary neuronal death beyond the primary injury zone.

Neuroplasticity and Synaptic Remodelling

Animal and cell culture studies show Cerebrolysin increases dendritic spine density, synaptic protein expression, and long-term potentiation. These structural changes are consistent with the neurotrophin receptor activation mechanism.

Anti-apoptotic Effects

Cerebrolysin reduces markers of apoptosis (programmed cell death) in stressed neurons via BDNF/TrkB and GDNF/RET receptor pathways. This is relevant to neurodegeneration, where progressive apoptosis of vulnerable neuron populations drives functional decline.

Metabolism Normalisation

Several studies document that Cerebrolysin normalises glucose metabolism in brain regions affected by Alzheimer’s disease — an effect that may be measured by FDG-PET imaging. The mechanism is not fully characterised but may involve BDNF-dependent effects on neuronal glucose transporter expression.

What the Evidence Actually Shows

Alzheimer’s Disease

The most extensively studied clinical application. Multiple RCTs, including several with the highest dose (10 mL/day IV) and longest duration, show:

• Cognitive improvement on neuropsychological testing (MMSE, ADAS-Cog) compared to placebo
• Global clinical impression improvement
• Effect sizes modest but consistent across trials

The Cochrane review (2019) of Cerebrolysin for Alzheimer’s concluded the evidence is encouraging but insufficient for firm conclusions due to trial quality concerns — primarily methodological issues in older trials and heterogeneity in study design. More recent trials with better methodology show more consistent benefit, particularly at 10 mL/day.

Key point from the evidence: Dose matters significantly. Lower doses (5 mL) show inconsistent effects; 10 mL/day IV shows more consistent cognitive benefit in the trials. Most researchers using IM rather than IV are effectively using lower systemic doses.

Stroke

Stronger evidence than Alzheimer’s in terms of consistency. Multiple trials show functional improvement in stroke patients when Cerebrolysin is administered within 24–72 hours of onset and continued for 10–21 days. A 2012 meta-analysis found significant improvement in neurological deficit scales. This is the most clinically robust Cerebrolysin indication.

Traumatic Brain Injury

Smaller evidence base but consistent directional benefit across available trials. Anti-excitotoxicity mechanism is particularly relevant in TBI. Used clinically in several countries for this indication.

Vascular Dementia

Multiple trials show benefit comparable to Alzheimer’s data. The anti-ischaemic mechanism aligns with vascular dementia pathology.

What Is Not Established

• Optimal dosing for non-acute (preventive/longevity) use in healthy subjects
• Whether benefit in Alzheimer’s disease scales down to meaningful cognitive enhancement in healthy individuals
• Long-term safety beyond 12-week trial periods
• Bioequivalence of IM vs IV administration
• How batch-to-batch variability in the extract affects clinical outcome
• Whether research-supplier Cerebrolysin equivalents match the pharmacopoeia-standard EVER Neuro Pharma product

Dosing Protocols (Research Context)

Important: Cerebrolysin is supplied in ampoules at 215.2 mg/mL. Common ampoule sizes: 1 mL, 2 mL, 5 mL, 10 mL. A 5 mL dose from 1 mL ampoules requires combining multiple ampoules — this is standard practice in clinical settings.

No reconstitution required — Cerebrolysin is a ready-to-use solution. Administer directly from the ampoule. IV infusion typically dilutes in 100 mL normal saline; IM is administered undiluted.

Combination with Semax: The combination protocol is covered in the Neuroprotection Stack guide.

Storage: 2–8°C (refrigerated). Do not freeze. Stable until the expiry date printed on the ampoule. Once opened, use immediately.

Summary

Cerebrolysin carries the highest clinical evidence burden of any compound reviewed on this site — multiple RCTs, Cochrane reviews, 70+ years of clinical use, and regulatory approval in major markets. It is also the most logistically demanding: injection only, ampoule format, temperature-sensitive, with batch variability inherent to biological extracts. The clinical evidence is built on specific doses (10 mL/day IV) in patient populations — extrapolation to lower IM doses in healthy subjects requires appropriate caution. For researchers focused on cognitive neuroprotection with the strongest possible evidence grounding, Cerebrolysin is where the data lives.

See also: Neuroprotection Stack: Cerebrolysin + Semax · Semax research review